About this Research Topic

Background

Patients with acute lymphoblastic leukemia (ALL) experience one of the most aggressive malignant disorders of blood and bone marrow, characterized by the overproduction of immature white blood cells. Most ALL cases are of B-cell origin, and half of the patients diagnosed with ALL are children, especially infants aged 1-4 years. Standard-of-care therapies, including intensive chemotherapy, risk stratification, minimal residual disease monitoring, and supportive clinical care, have offered remarkable advances in the treatment of ALL and allowed for complete hematologic remission (CR) in most pediatric and adult patients. Despite these advanced treatment results and the increased overall survival (OS) of newly diagnosed patients, those suffering from relapsed or refractory disease (R/R ALL) do not share the same success. R/R ALL presents with a dismal prognosis and an OS of 3 to 12 months, depending mainly on the duration of the first remission. To overcome this medical challenge, targeted therapies have started to enter the arena, aiming at generating better patient outcomes with less toxicity and a greater probability of proceeding to allogeneic hematopoietic stem cell transplantation (alloHSCT).

This Research Topic focuses on the current landscape of novel targeted immunotherapies and molecular therapies for R/R ALL, their appropriate use in children and adult patients, and how they are incorporated into recent clinical practice. In addition, it aims to expand knowledge on the molecular pathways involved in ALL and how these pathways are being therapeutically targeted. Bispecific T-cell engager (BiTE) immunotherapy constructs crosslink the CD3 component of cytotoxic T-cells with the CD19 antigen on the surface of tumor cells, resulting in the activation of T-cells and the release of cytotoxic proteins. Inotuzumab ozogamicin is an anti-CD22 antibody conjugated to calicheamicin. It binds to cell surface CD22, and the drug is internalized into leukemic cells while calicheamicin is released, resulting in DNA damage and subsequent cell apoptosis. Chimeric antigen receptor T-cells (CAR T-cells) immunotherapy aims at harvesting patient-specific T-cells and reengineering them to express a new antigen recognition receptor to encounter and destroy the CD19 antigen on the leukemic cell surface. Tyrosine kinase inhibitors (TKIs) disrupt the signal transduction pathways of protein kinases in several ways and are used for the treatment of Philadelphia chromosome-positive (Ph+) ALL in children and adults.

Our aim is to advance the understanding of novel and effective treatment strategies in the ALL setting for children and adult patients, and to highlight the important challenges to be addressed in the upcoming years.

The objectives of this Research Topic are as follows:

1. Promote knowledge of the novel treatment strategies for children and adults with R/R ALL.
2. Identify and characterize potential mechanisms of resistance to immunotherapies, and potential adverse effects and toxicity.
3. Provide information on the appropriate use of different immunotherapies according to specific clinical conditions.
4. Explore future perspectives on whether immunotherapies could be incorporated as frontline therapies in parallel with or sequentially to standard-of-care treatment.

Clinicians, molecular biology, and hematology researchers are kindly invited to contribute to this article collection by submitting original research, reviews, clinical trials, mini-reviews, case, and systematic review articles.

All above-mentioned article types will be considered for this Research Topic. For more information regarding particular article types, please visit: https://www.frontiersin.org/journals/medicine/for-authors/article-types

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Data Report
• Editorial
• General Commentary
• Methods
• Mini Review
• Opinion
• ... View all formats

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Article types

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Data Report
• Editorial
• General Commentary
• Methods
• Mini Review
• Opinion
• Original Research
• Perspective
• Review
• Study Protocol
• Systematic Review

Keywords: Hematology, Acute Lymphoblastic Leukemia, relapsed/refractory, hematologic malignancies, immunotherapy, molecular therapy, frontline treatment

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Frequently asked questions

• What is a Research Topic?

  Frontiers' Research Topics are collaborative hubs built around an emerging theme.Defined, managed, and led by renowned researchers, they bring communities together around a shared area of interest to stimulate collaboration and innovation.

  Unlike section journals, which serve established specialty communities, Research Topics are pioneer hubs, responding to the evolving scientific landscape and catering to new communities.

• Why does Frontiers publish Research Topics? 

  The goal of Frontiers' publishing program is to empower research communities to actively steer the course of scientific publishing. Our program was implemented as a three-part unit with fixed field journals, flexible specialty sections, and dynamically emerging Research Topics, connecting communities of different sizes and maturity.

  Research Topics originate from the scientific community. Many of our Research Topics are suggested by existing editorial board members who have identified critical challenges or areas of interest in their field.

• Why are Research Topics important for journals?

  As an editor, Research Topics will help you build your journal, as well as your community, around emerging, cutting-edge research. As research trailblazers, Research Topics attract high-quality submissions from leading experts all over the world.

  A thriving Research Topic can potentially evolve into a new specialty section if there is sustained interest and a growing community around it.

• How do we ensure the quality of articles within Research Topics?

  Each Research Topic must be approved by the specialty chief editor, and it falls under the editorial oversight of our editorial boards, supported by our in-house research integrity team. The same standards and rigorous peer review processes apply to articles published as part of a Research Topic as for any other article we publish.

  In 2023, 80% of the Research Topics we published were edited or co-edited by our editorial board members, who are already familiar with their journal's scope, ethos, and publishing model. All other topics are guest edited by leaders in their field, each vetted and formally approved by the specialty chief editor.

• What are the benefits of publishing my article in a Research Topic?

  Publishing your article within a Research Topic with other related articles increases its discoverability and visibility, which can lead to more views, downloads, and citations. Research Topics grow dynamically as more published articles are added, causing frequent revisiting, and further visibility.

  As Research Topics are multidisciplinary, they are cross-listed in several fields and section journals – increasing your reach even more and giving you the chance to expand your network and collaborate with researchers in different fields, all focusing on expanding knowledge around the same important topic.

  Our larger Research Topics are also converted into ebooks and receive social media promotion from our digital marketing team.

   
• What types of articles can be published in a Research Topic?

  Frontiers offers multiple article types, but it will depend on the field and section journals in which the Research Topic will be featured. The available article types for a Research Topic will appear in the drop-down menu during the submission process.

  Check available article types here 

• Can I suggest a new Research Topic? 

  Yes, we would love to hear your ideas for a topic. Most of our Research Topics are community-led and suggested by researchers in the field. Our in-house editorial team will contact you to talk about your idea and whether you’d like to edit the topic. If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. 

  Suggest your topic here 

• Who leads a Research Topic? 

  A team of guest editors (called topic editors) lead their Research Topic. This editorial team oversees the entire process, from the initial topic proposal to calls for participation, the peer review, and final publications.

  The team may also include topic coordinators, who help the topic editors send calls for participation, liaise with topic editors on abstracts, and support contributing authors. In some cases, they can also be assigned as reviewers.

• What is the role of a topic editor?

  As a topic editor (TE), you will take the lead on all editorial decisions for the Research Topic, starting with defining its scope. This allows you to curate research around a topic that interests you, bring together different perspectives from leading researchers across different fields and shape the future of your field. 

   

  You will choose your team of co-editors, curate a list of potential authors, send calls for participation and oversee the peer review process, accepting or recommending rejection for each manuscript submitted.

• What support will I receive when editing a new Research Topic? 

  As a topic editor, you're supported at every stage by our in-house team. You will be assigned a single point of contact to help you on both editorial and technical matters. Your topic is managed through our user-friendly online platform, and the peer review process is supported by our industry-first AI review assistant (AIRA).

• As a junior researcher, can I be involved in editing a Research Topic? 

  If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. This provides you with valuable editorial experience, improving your ability to critically evaluate research articles and enhancing your understanding of the quality standards and requirements for scientific publishing, as well as the opportunity to discover new research in your field, and expand your professional network.

• Can I get a certificate for editing a Research Topic?

  Yes, certificates can be issued on request. We are happy to provide a certificate for your contribution to editing a successful Research Topic.

• Who will I collaborate with?

  Research Topics thrive on collaboration and their multi-disciplinary approach around emerging, cutting-edge themes, attract leading researchers from all over the world.

• How long does it take to publish a Research Topic?

  As a topic editor, you can set the timeline for your Research Topic, and we will work with you at your pace. Typically, Research Topics are online and open for submissions within a few weeks and remain open for participation for 6 – 12 months. Individual articles within a Research Topic are published as soon as they are ready.

  Find out more about our Research Topics

• What fee support is available to authors publishing in a Research Topic?

  Our fee support program ensures that all articles that pass peer review, including those published in Research Topics, can benefit from open access – regardless of the author's field or funding situation.

  Authors and institutions with insufficient funding can apply for a discount on their publishing fees. A fee support application form is available on our website.

• Will there be a printed version of my Research Topic?

  In line with our mission to promote healthy lives on a healthy planet, we do not provide printed materials. All our articles and ebooks are available under a CC-BY license, so you can share and print copies.